CLS releases CE-marked new version of Thermoguide™ Workstation for use also with MRI scanners from GE Healthcare
Clinical Laserthermia Systems AB (publ) announces today the release of a CE-marked new version of TRANBERG® | Thermoguide™ Workstation. The new version is developed for use also with MRI scanners in GE Healthcare's product range.
The Thermoguide™ Workstation, of the TRANBERG® | Thermal Therapy System continuously captures and processes images and thermometry data from an MRI scanner in real-time. The resulting information is presented graphically, as temperature maps and calculated ablation volume, superimposed on high-resolution anatomical images. In addition, Thermoguide™ Workstation includes features for precise monitoring and control of the ablation procedure, all developed with procedural safety and efficacy in mind.
- After a successful collaboration with GE Healthcare and our partner Image Guided Therapy, we are now releasing a CE-marked new version of TRANBERG Thermoguide Workstation that can be used also with MRI scanners from GE Healthcare. This means we are broadening our market significantly as we can now offer our product line to European customers with MRI scanners from both GE Healthcare as well as Siemens Healthineers says Perjan Pleunis, VP Sales in Europe at CLS.
- An important goal for us this year is to be able to offer our product line to European customers having MRI scanners from all the leading manufacturers. To reach this goal CLS is now also working closely with Philips to include their MRI scanners in an upcoming release, says Dan J. Mogren, Acting CEO of CLS.
About TRANBERG® | ThermoguideTM Workstation
Thermoguide Workstation connects TRANBERG® | Thermal Therapy System with an MRI scanner and visualizes tissue temperature and extent of tissue ablation performed, both numerically and graphically on the image sequences of the treatment area that are continuously generated by the MRI scanner. By accessing image sequences with minimal delay, the software enables tissue temperature measurements in real time as well as calculation of ablation size with high precision and accuracy. All clearly presented in a graphic user interface to give treating physicians optimal guidance and a safe and efficient workflow during treatment.
Contact information:
Dan J. Mogren, Acting CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 901140 E-mail: dan.mogren@clinicallaser.com
About CLS and TRANBERG
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. All components of the TRANBERG®|Thermal Therapy Systems have received EU-wide regulatory approval as medical devices (CE-marked class II) for the treatment of soft tissue lesions. CLS is developing its systems to get CE-mark class III for disposable TRANBERG laser applicators to be used in brain as well as expanding the current CE-mark for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-04-2022 14:00 CET.